Navigation Links
WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008
Date:2/21/2008

Earnings Conference Call to be held on March 13, 2008 at 9:00 am (Eastern)

/ 6:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong)

SHANGHAI, China, Feb. 21 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) ("WuXi PharmaTech" or "the Company"), the leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release unaudited financial results for the fourth quarter and full year ended December 31, 2007 after the US market close on Wednesday, March 12, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The earnings release will be available on the investor relations page of its website at http://www.wuxipharmatech.com .

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 9:00 am (Eastern) / 6:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong) on Thursday, March 13, 2008 to discuss its 2007 fourth quarter and full year financial results and recent business activity. The conference call may be accessed by calling:

United States

Toll Free: +1-888-596-2633

Toll: +1-913-312-1234

China, Northern Region

Toll Free: +10-800-714-0970

China, Southern Region

Toll Free: +10-800-140-0945

Hong Kong

Toll Free: +800-965-503

United Kingdom

Toll Free: +0808-101-1402

A telephone replay will be available shortly after the call until April 12, 2008 at (US) +1-888-203-1112/ (HK) +800-901-108 / (China, Southern Region) +10-800-140-1178 / (China, Northern Region) +1-719-457-0820 / (UK) +0808-101- 1153. Passcode: 2224172.

A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech's website at http://www.wuxipharmatech.com .

About WuXi PharmaTech (Cayman) Inc.

WuXi PharmaTech, headquartered in Shanghai, China, is the leading global pharmaceutical, biotechnology and medical device R&D outsourcing company. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory, research manufacturing, biologics testing and manufacturing services throughout the drug and medical device research and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device research and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Investor Contact:

Dr. Hai Mi, Vice President, Corporate Communications

WuXi PharmaTech Co., Ltd

Tel: +86-21-5046-3726

Email: ir@pharmatechs.com

Investor Relations (US):

Mahmoud Siddig, Director

Taylor Rafferty

Tel: +1-212-889-4350

Email: Pharmatechs@taylor-rafferty.com

Investor Relations (HK):

Ruby Yim, Managing Director

Taylor Rafferty

Tel: +852-3196-3712

Email: Pharmatechs@taylor-rafferty.com

Media Contact:

John Dooley

Taylor Rafferty

Tel: +1-212-889-4350

Email: Pharmatechs@taylor-rafferty.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Completes Acquisition of AppTec
2. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
3. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
4. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
5. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
6. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
7. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
8. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
9. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
10. WuXi PharmaTech Announces Second Quarter 2007 Results
11. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
Breaking Biology News(10 mins):